Antisoma is a London Stock Exchange-listed biopharmaceutical company that develops novel products for the treatment of cancer.
The company has operations in London, UK and Cambridge, MA.
Antisoma, Inc, Clinical Operations VP Chris Smyth said that they are pleased that the development of AS1413 has qualified for this recognition, and look forward to reporting the key phase III data on the drug in the near future.
QTDP grants are awarded to projects that show a reasonable potential to result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions, reduce the long-term growth of health care costs in the US, or significantly advance the goal of curing cancer within 30 years.